|Articles|March 1, 2003
Adios, Lentigo
Oklahoma City -- Topical application of the immune response modifier imiquimod appears to be an effective and reasonably well-tolerated treatment for lentigo maligna, according to research conducted by dermatologists from the University of Oklahoma Health Sciences Center, Oklahoma City.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Transformative Advances This Year and Beyond
2
FDA Proposes Expansion of US Sunscreen Ingredient Standards with Bemotrizinol
3
Phase 3b Study Confirms Ligelizumab’s Consistent CSU Control
4
Global Hidradenitis Suppurativa Atlas (GHiSA) Finds HS Affects 1% of the World's Population
5














